Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast cancers that have a poor clinical outcome. Although no approved targeted therapy is available for TNBCs, molecular-profiling efforts have revealed promising molecular targets, with several candidate compounds having now entered clinical trials for TNBC patients. However, initial results remain modest, thereby highlighting challenges potentially involving intra- and intertumoral heterogeneity and acquisition of therapy resistance. We present a comprehensive review on emerging targeted therapies for treating TNBCs, including the promising approach of immunotherapy and the prognostic value of tumor-infiltrating lymphocytes. We discuss the impact of pathway rewiring in the acquisition of drug resistance, and the prospect of employing combination therapy strategies to overcome challenges towards identifying clinically-viable targeted treatment options for TNBC.

[1]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Morgan,et al.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[5]  A. Gown,et al.  Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. , 1995, Cancer research.

[6]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[8]  S. Schnitt,et al.  Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.

[9]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[11]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[12]  S. Leung,et al.  Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. , 2008, Clinical breast cancer.

[13]  S. Hochwald,et al.  Targeting receptor tyrosine kinases in solid tumors. , 2013, Surgical oncology clinics of North America.

[14]  W. Jonat,et al.  In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells , 2010, BMC Cancer.

[15]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[16]  J. Stagg,et al.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects , 2013, Therapeutic advances in medical oncology.

[17]  P. Dent,et al.  Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells , 2010, Molecular Pharmacology.

[18]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Kholodenko,et al.  Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. , 2012, Biochemical Society transactions.

[20]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[22]  John E. Harlan,et al.  Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor , 2011, Clinical Cancer Research.

[23]  Barbara L. Smith,et al.  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  John Quackenbush,et al.  Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer , 2009, Clinical Cancer Research.

[25]  Christos Sotiriou,et al.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Andrew R. Green,et al.  Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status , 2009, Breast Cancer Research and Treatment.

[27]  G. Mills,et al.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.

[28]  Adam A. Margolin,et al.  Prognostic Models for Breast Cancer Systematic Analysis of Challenge-Driven Improvements in Molecular , 2013 .

[29]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[30]  Miles A. Miller,et al.  The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells , 2013, Science Signaling.

[31]  P. Furth.  STAT signaling in different breast cancer sub-types , 2014, Molecular and Cellular Endocrinology.

[32]  Jakić-Razumović Jasminka,et al.  High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer , 2011, Medical Oncology.

[33]  M. Hung,et al.  Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides , 2013, PloS one.

[34]  Alex Arenas,et al.  Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules , 2010, BMC Cancer.

[35]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[36]  G. Kroemer,et al.  Prognostic and predictive impact of intra- and peritumoral immune infiltrates. , 2011, Cancer research.

[37]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[38]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[39]  J. Montero,et al.  Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer , 2014, Oncogene.

[40]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[41]  Lukas Balek,et al.  Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation , 2012, PloS one.

[42]  Yan Shi,et al.  PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[43]  P. Stephens,et al.  Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents , 2014, Molecular Cancer Therapeutics.

[44]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[45]  R. Gelber,et al.  Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Adam A. Margolin,et al.  Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.

[47]  D. Nielsen,et al.  A systematic review of bevacizumab efficacy in breast cancer. , 2014, Cancer treatment reviews.

[48]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[49]  B. Smith.  Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects. , 2011, Journal of the National Cancer Institute.

[50]  S. Dent.  The role of VEGF in triple-negative breast cancer: where do we go from here? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  G. Mills,et al.  Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. , 2014, Cancer research.

[52]  P. Sorger,et al.  Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays , 2013, Oncogene.

[53]  C. Leslie,et al.  Linking signaling pathways to transcriptional programs in breast cancer , 2014, Genome research.

[54]  H. Doihara,et al.  Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[55]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[56]  G. Hortobagyi,et al.  High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. , 2012, The oncologist.

[57]  A. Ashworth,et al.  FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo , 2011, Clinical Cancer Research.

[58]  Jeremy S Logue,et al.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. , 2012, Genes & development.

[59]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Schadendorf,et al.  Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. , 2013, The Lancet. Oncology.

[61]  J. Gabrilove,et al.  The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. , 1997, Blood.

[62]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[64]  David R. Croucher,et al.  Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. , 2010, Cancer research.

[65]  T. Shibata,et al.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[66]  P. Watson,et al.  Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer , 2011, Breast Cancer Research.

[67]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[68]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[69]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[70]  Frederick S. Vizeacoumar,et al.  RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs , 2013, PloS one.

[71]  A. Sieuwerts,et al.  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment , 2014, Clinical Cancer Research.

[72]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[73]  H. Wildiers,et al.  Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer , 2013, Breast Cancer Research.

[74]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[75]  S. Hilsenbeck,et al.  STAT3 Signaling Is Activated Preferentially in Tumor‐Initiating Cells in Claudin‐Low Models of Human Breast Cancer , 2014, Stem cells.

[76]  E. Gonzalez-Billalabeitia,et al.  Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer , 2014, Breast Cancer Research.

[77]  J. Schlessinger,et al.  Receptor tyrosine kinases: legacy of the first two decades. , 2014, Cold Spring Harbor perspectives in biology.

[78]  M. Sporn,et al.  The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice , 2014, Cancer Prevention Research.

[79]  U. Korf,et al.  Subtyping of breast cancer using reverse phase protein arrays , 2014, Expert review of proteomics.

[80]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[81]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[82]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[83]  Tai-Hsien Ou Yang,et al.  Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment , 2013, Science Translational Medicine.

[84]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[85]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[86]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[87]  S. Fox,et al.  Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women , 2013, Breast Cancer Research and Treatment.

[88]  B. Stewart,et al.  World cancer report 2014. , 2014 .

[89]  G. Sauter,et al.  Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[90]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[91]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[92]  S. Loi,et al.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.

[93]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[94]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  M. Yamaguchi,et al.  Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. , 2012, Human pathology.

[96]  Yun Dai,et al.  CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. , 2011, Molecular interventions.

[97]  G. Mills,et al.  Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance , 2012, Nature Medicine.

[98]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[99]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[100]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[101]  R. Dummer,et al.  Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.

[102]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  P. Dent,et al.  Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells , 2002, Cancer biology & therapy.

[104]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[105]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[106]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Xiaojun Zhou,et al.  C-kit and PDGFRA gene mutations in triple negative breast cancer. , 2014, International journal of clinical and experimental pathology.

[108]  I. Gromova,et al.  Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer* , 2012, Molecular & Cellular Proteomics.

[109]  E. Ibrahim,et al.  The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis , 2014, Breast Cancer Research and Treatment.

[110]  M. Smyth,et al.  Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. , 2014, Cancer research.

[111]  M. Audeh.  Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition , 2014, Pharmacogenomics and personalized medicine.

[112]  F. Bertucci,et al.  Prognostic and predictive value of PDL1 expression in breast cancer , 2014, Oncotarget.

[113]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[114]  E. Winer,et al.  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Gordon B Mills,et al.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors , 2014, Breast Cancer Research.

[116]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.

[117]  S. Duffy,et al.  Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer , 2013, Breast Cancer Research.

[118]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[119]  T. Sørlie,et al.  Triple‐negative breast cancer: Present challenges and new perspectives , 2010, Molecular oncology.

[120]  P H Watson,et al.  Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer , 2012, British Journal of Cancer.

[121]  Yonghe Li,et al.  The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer , 2012, Journal of cellular biochemistry.

[122]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[123]  Yun Wu,et al.  Mesothelin expression and survival outcomes in triple receptor negative breast cancer. , 2013, Clinical breast cancer.

[124]  J. Reis-Filho,et al.  Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. , 2015, Journal of the National Cancer Institute.

[125]  C. Cordon-Cardo,et al.  Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.

[126]  Vamsidhar Velcheti,et al.  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.

[127]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[128]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[129]  Wei Zhou,et al.  ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors , 2012, Molecular Cancer Therapeutics.

[130]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[131]  M. Smyth,et al.  Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.

[132]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[133]  Anita Grigoriadis,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[134]  A. Ashworth,et al.  Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. , 2012, Cancer discovery.

[135]  Michael Boutros,et al.  Screens, maps & networks: from genome sequences to personalized medicine. , 2012, Current opinion in genetics & development.

[136]  Su-In Lee,et al.  The proteomic landscape of triple-negative breast cancer. , 2015, Cell reports.

[137]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[138]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[139]  M. Ellis,et al.  Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. , 2012, The Journal of clinical investigation.

[140]  Shelley M Enger,et al.  Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[141]  Albino Martins,et al.  Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression , 2005, Breast Cancer Research.

[142]  E. McDermott,et al.  Src: a potential target for the treatment of triple-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[143]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[145]  Frances M. G. Pearl,et al.  Therapeutic opportunities within the DNA damage response , 2015, Nature Reviews Cancer.

[146]  F. Bertucci,et al.  High expression of indoleamine 2,3‐dioxygenase in the tumour is associated with medullary features and favourable outcome in basal‐like breast carcinoma , 2012, International journal of cancer.

[147]  A. Vargas,et al.  Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor , 2013, The Journal of Nuclear Medicine.

[148]  E. Winer,et al.  Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer , 2010, Clinical Cancer Research.

[149]  Gordon B Mills,et al.  Proteomic classification of breast cancer. , 2012, Current drug targets.

[150]  Adilson E Motter,et al.  Improved network performance via antagonism: From synthetic rescues to multi-drug combinations , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[151]  B. Leyland-Jones,et al.  Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner , 2013, PloS one.

[152]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[153]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[154]  S. Aparicio,et al.  The omics of triple-negative breast cancers. , 2014, Clinical chemistry.

[155]  D. Noh,et al.  A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients , 2014, Breast Cancer Research and Treatment.

[156]  H. Moses,et al.  Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer , 2014, Breast Cancer Research.

[157]  P. Pandolfi,et al.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.

[158]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  B. Aggarwal,et al.  Curcumin improves the therapeutic efficacy of Listeriaat-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1 , 2013, Cancer medicine.

[160]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[161]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[162]  A. Di Leo,et al.  Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy , 2014, Current opinion in oncology.

[163]  G. Shapiro,et al.  Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.

[164]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[165]  L. Pusztai,et al.  PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Cancer Immunology Research.

[166]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[167]  S. Davidson,et al.  A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[168]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[169]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[170]  Kwok-Kin Wong,et al.  COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.

[171]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[172]  W. Koch,et al.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy , 2012, Cell cycle.

[173]  A. Goldhirsch,et al.  Cancer-testis antigen expression in triple-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[174]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[175]  I. Takahashi,et al.  UCN-01, a selective inhibitor of protein kinase C from Streptomyces. , 1987, The Journal of antibiotics.

[176]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  S. Barni,et al.  The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.

[178]  A. Sartori,et al.  Controlling DNA-end resection: a new task for CDKs , 2013, Front. Genet..

[179]  L. Miele,et al.  Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells , 2014, Vascular cell.

[180]  Teruhiko Yoshida,et al.  Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells , 2012, Cancer science.

[181]  Andrew H. Beck,et al.  Targeting Akt3 signaling in triple-negative breast cancer. , 2014, Cancer research.

[182]  M. Shimizu,et al.  G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. , 1997, Cancer research.

[183]  H. Brinkhaus,et al.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.

[184]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  G. Mills,et al.  cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer , 2014, Journal of Cancer.

[187]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[188]  G. Giles,et al.  Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers , 2010, Proceedings of the National Academy of Sciences.

[189]  S. Rodenhuis,et al.  Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers , 2013, British Journal of Cancer.

[190]  A. Eastman,et al.  Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[191]  C. Moreno,et al.  Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells , 2013, Journal of Translational Medicine.

[192]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[193]  Markus K. Muellner,et al.  Targeting a cell state common to triple-negative breast cancers , 2015, Molecular systems biology.

[194]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[195]  James S. Duncan,et al.  Defining the expressed breast cancer kinome , 2012, Cell Research.

[196]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[197]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[198]  H. Rugo,et al.  Triple-Negative Breast Cancer: Role of Antiangiogenic Agents , 2010, Cancer journal.

[199]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[200]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[201]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  Pradip De,et al.  Wnt signaling in triple negative breast cancer is associated with metastasis , 2013, BMC Cancer.

[203]  J. Pietenpol,et al.  Subtyping of triple‐negative breast cancer: Implications for therapy , 2015, Cancer.

[204]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[205]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[206]  S. Leung,et al.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.

[207]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[208]  Justin M Balko,et al.  Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. , 2014, Discovery medicine.

[209]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[210]  C. Perou,et al.  Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver , 2012, Genetics.

[211]  P. Tan,et al.  Role of inflammatory infiltrates in triple negative breast cancer , 2015, Journal of Clinical Pathology.

[212]  Dhara N. Amin,et al.  Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver , 2010, Science Translational Medicine.

[213]  Fan Zhang,et al.  Computational cell fate modelling for discovery of rewiring in apoptotic network for enhanced cancer drug sensitivity , 2015, BMC Systems Biology.

[214]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[215]  G. Kroemer,et al.  The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe , 2004, Oncogene.

[216]  E. Alba,et al.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer , 2010, BMC Cancer.

[217]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[218]  S. O'toole,et al.  TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers , 2012, Molecular and Cellular Biology.

[219]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[220]  A. Luini,et al.  Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[221]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[222]  J. Ahn,et al.  Prognostic impact of FOXP3 expression in triple-negative breast cancer , 2013, Acta oncologica.

[223]  S. Lakhani,et al.  Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer , 2014, Oncogenesis.

[224]  A. Vargas,et al.  Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer , 2014, Oncotarget.

[225]  M. Hedayati,et al.  Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody , 2013, Molecular Cancer Therapeutics.

[226]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[227]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[228]  Shantanu Banerji,et al.  Molecular Pathways Molecular Pathways : PI 3 K Pathway Targets in Triple-Negative Breast Cancers , 2013 .

[229]  I. Ellis,et al.  Are Triple-Negative and Basal-Like Breast Cancer Synonymous? , 2008, Clinical Cancer Research.

[230]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[231]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[232]  James S. Duncan,et al.  The dynamic nature of the kinome. , 2013, The Biochemical journal.

[233]  G. Chenevix-Trench,et al.  A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy , 2014, Nucleic acids research.

[234]  E. Ibrahim,et al.  Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis , 2012, BMC Cancer.

[235]  L. Symington,et al.  Double-strand break end resection and repair pathway choice. , 2011, Annual review of genetics.

[236]  G. Mills,et al.  Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair , 2014, Nature Communications.

[237]  K. Schalper.  PD-L1 expression and tumor-infiltrating lymphocytes , 2014, Oncoimmunology.

[238]  Stephen J. Elledge,et al.  Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair , 2015, Nature.

[239]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[240]  Ana Lluch,et al.  Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. , 2012, Cancer treatment reviews.

[241]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[242]  N. Ueno,et al.  Targeted Therapy , 2011 .

[243]  P. Dent,et al.  Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. , 2001, Cancer research.

[244]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[245]  M. Duffy,et al.  cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? , 2014, Expert opinion on therapeutic targets.

[246]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[247]  B. Yadav,et al.  Systemic treatment strategies for triple-negative breast cancer. , 2014, World journal of clinical oncology.

[248]  L. Skoog,et al.  Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[249]  L. Bégin,et al.  Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma , 2003, Cancer.